Barentz, a distributor of ingredients in the life science markets, has acquired a majority shareholding in Czech Republic-based IMCoPharma. As a full-service pharmaceutical company IMCoPharma researches, markets and distributes a broad portfolio of products and services in the CIS region and Ukraine. The active pharmaceutical ingredients, excipients and final dosage forms are manufactured by leading European pharmaceutical manufacturers.

“We are pleased with this excellent opportunity,” said Hidde van der Wal, chief executive officer, Barentz. “IMCoPharma is a true leader and authority in this business segment in the CIS countries and Ukraine. This strategic investment gives us the licenses and immediate access to do business with all pharmaceutical companies in this huge region. It will certainly lead to strong synergies with our existing suppliers and portfolio of ingredients.”
 
Ivan Mikes, founder and chief executive officer, IMCoPharma, said, “With Barentz on board we can further build on our success. It will give us many new business opportunities to strengthen our position as a leader in the CIS region and Ukraine. I am convinced this is a perfect fit and we look forward to a fruitful co-operation and common growth.